Advertisement

OMEZ 20 (capsule)

Main information

  • Trade name:
  • OMEZ 20 (capsule)
  • Available from:
  • Dr-reddy
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug
Advertisement

Documents

Localization

  • Available in:
  • OMEZ 20 (capsule)
    South Africa
  • Language:
  • English

Other information

Advertisement

Status

  • Source:
  • Sounth African Electronic Package Inserts
  • Last update:
  • 09-08-2016

Patient Information leaflet

Advertisement

OMEZ 10 (capsule)

OMEZ 20 (capsule)

OMEZ 40 (capsule)

SCHEDULING STATUS:

S4

PROPRIETARY NAME

(and dosage form):

OMEZ 10 (capsule)

OMEZ 20 (capsule)

OMEZ 40 (capsule)

COMPOSITION:

OMEZ 10: Each capsule contains omeprazole 10 mg

OMEZ 20: Each capsule contains omeprazole 20 mg

OMEZ 40: Each capsule contains omeprazole 40 mg

PHARMACOLOGICAL CLASSIFICATION

A 11.4.3 Medicines acting on the gastrointestinal tract –Other

PHARMACOLOGICAL ACTION

Omeprazole is an inhibitor of the gastric proton pump (H+, K+-ATPase). It inhibits both basal and stimulated gastric acid

secretion by parietal cells, whether induced by acetylcholine, gastrin or histamine.

Omeprazole has no effect on acetylcholine, histamine or gastric receptors.

Pharmacokinetics

Orally administered omeprazole is well absorbed but to a variable extent. Absorption of omeprazole takes place in the

small intestine and is usually completed within three to six hours. Bioavailability depends on dose and gastric pH and

may reach 70% with repeated administration. Food has no influence on the bioavailability of omeprazole.

Omeprazole is more than 95% bound to plasma proteins. Clearance from the circulation is by hepatic metabolism with a

plasma half-life of 30 to 90 minutes.

Hepatic metabolism occurs primarily via the cytochrome P450 (CYP) isoform (CYP2C19). The inactive metabolites are

excreted mainly in the urine (80%) whilst the remaining 20% are excreted via the faeces. The average half-life of the

terminal phase of the plasma concentration-time curve is approximately 40 minutes. There is no change in plasma half-

life during treatment. The inhibition of acid secretion is related to the area under the plasma concentration - time curve

(AUC) and not to the actual plasma concentration at a given time.

INDICATIONS

OMEZ is indicated in:

Adults

Treatment of duodenal ulcer, including prevention of relapse gastric ulcer and reflux oesophagitis.

Long-term management of reflux oesophagitis and Zollinger-Ellison Syndrome.

Symptomatic relief of heartburn in patients with gastro-oesophageal reflux disease (GORD) and the short-term relief of

functional dyspepsia.

Helicobacter pylori-positive duodenal ulcers as part of an eradication programme with appropriate antibiotics.

Treatment of non-steroidal anti-inflammatory drugs (NSAID)-associated gastric and/or duodenal ulcer/erosions.

Reduction of the risk to develop gastric and/or duodenal ulcer/erosions and reduction of the risk of relapse for

previously healed gastric and/or duodenal ulcer/erosions in patients on NSAID treatment.

Children

Short-term (up to 3 months) treatment of severe ulcerative reflux oesophagitis resistant to previous medical treatment.

CONTRA-INDICATIONS

Hypersensitivity to any of the ingredients

Safety in pregnancy and lactation has not been established

WARNINGS

Symptomatic response to OMEZ therapy does not preclude the presence of gastric ulcer or malignancy or a malignant

disease of the oesophagus. The administration of OMEZ in this situation may delay diagnosis (see Special Precautions).

Hepatic impairment may require a reduction in dose (see DOSAGE AND DIRECTIONS FOR USE).

THERE IS VERY LIMITED EXPERIENCE WITH THE USE OF OMEZ IN CHILDREN.

THE LONG-TERM SAFETY OF OMEZ IN PATIENTS WITH RENAL AND/OR HEPATIC IMPAIRMENT HAS

NOT BEEN ESTABLISHED.

THIS MEDICINE MAY LEAD TO DROWSINESS AND IMPAIRED CONCENTRATION THAT MAY BE

AGGRAVATED BY THE SIMULTANEOUS INTAKE OF ALCOHOL OR OTHER CENTRAL NERVOUS SYSTEM

DEPRESSANTS. PATIENTS SHOULD BE ADVISED, PARTICULARLY AT THE INITIATION OF THERAPY,

AGAINST TAKING CHARGE OF VEHICLES OR MACHINERY OR PERFORMING POTENTIALLY

HAZARDOUS TASKS WHERE LOSS OF CONCENTRATION COULD LEAD TO ACCIDENTS.

INTERACTIONS

OMEZ is metabolised via the hepatic P450 cytochrome enzyme system, which may affect the metabolism of other

medications metabolised by these enzymes, when given concomitantly. The elimination of diazepam, warfarin and

phenytoin may be prolonged when OMEZ is given concomitantly.

Monitoring of INR and phenytoin serum levels is recommended and dosage reductions may be necessary when OMEZ is

given concomitantly. There is a possible interaction of OMEZ with digoxin and a 10% increase in digoxin

bioavailability may be expected.

There may be interactions with other medicines, which are also metabolised via the cytochrome P450 enzyme system.

PREGNANCY AND LACTATION

Safety in pregnancy and lactation has not been established (see CONTRAINDICATIONS).

DOSAGE AND DIRECTIONS FOR USE

OMEZ is recommended to be given in the morning and swallowed whole with a half glass of liquid. The capsules should

not be chewed or crushed.

RECOMMENDED DOSAGES FOR ADULTS

Duodenal ulcer

20 mg once daily for two to four weeks.

In some duodenal ulcer patients refractory to other treatment regimens, 40 mg once daily may be effective.

Prevention of relapse in patients with duodenal ulcer

10 mg once daily.

If necessary the dose can be increased to 20 –40 mg once daily.

The above recommended dosage regimens are inclusive of Helicobacter pylori-positive duodenal ulcers as part of the

eradication programme with appropriate antibiotics.

Gastric ulcer and reflux oesophagitis

20 mg once daily for four to eight weeks.

In some gastric ulcer and reflux oesophagitis patients refractory to other treatment regimens, 40 mg once daily may be

effective.

For the long-term management of patients with reflux oesophagitis the recommended dose is 20 mg once daily. If

necessary the dose can be increased to 20 –40 mg once daily.

In patients with severe or symptomatic recurrent reflux oesophagitis treatment can be continued with OMEZ at a dosage

of 20 mg once daily.

NSAID-associated gastro-duodenal lesions with or without continued NSAID treatment

20 mg once daily.

In most patients healing occurs within 4 weeks. For patients who may not be fully healed after the initial course healing

usually occurs during a further 4 weeks of treatment.

Prevention of NSAID-associated gastro-duodenal lesions and dyspeptic symptoms

20 mg once daily.

Symptomatic gastro-oesophageal reflux disease

20 mg daily.

Patients may respond adequately to 10 mg daily, therefore individual dose adjustments should be considered.

Patients may respond adequately to 10 mg daily, therefore individual dose adjustments should be considered.

If symptom control has not been achieved after 2 weeks of treatment with 20 mg daily further investigation is

recommended.

Zollinger-Ellison Syndrome

60 mg once daily.

The dosage should be adjusted individually and treatment continued as long as it is clinically indicated. With doses

above 80 mg daily the dose should be divided and given twice daily.

There is very limited experience with the use of OMEZ in children (see WARNINGS).

Severe ulcerative reflux oesophagitis in children from one year and older

Recommended dosages:

Weight: Dosage:

10 –20 kg: 10 mg once daily. If needed increase to 20 mg once daily

>20 kg: 20 mg once daily. If needed increase to 40 mg once daily

Elderly

Dose reductions are not necessary in elderly patients.

The long-term safety of OMEZ in patients with renal and hepatic impairment has not been established (see WARNINGS).

Impaired renal function

Dose reductions are not necessary in renal impairment.

Impaired hepatic function

Bioavailability and plasma half-life of OMEZ are increased in patients with impaired hepatic function, therefore a daily

dose of 10 –20 mg is generally sufficient.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS

Side-effects

Blood and lymphatic system disorders

Rare: Leucopenia, thrombocytopenia, agranulocytosis, pancytopenia

Endocrine disorders

Rare: Gynaecomastia

Metabolic and nutritional disorders

Rare: Hyponatraemia

Psychiatric disorders

Rare: Reversible mental confusion, agitation, aggression, depression and hallucinations (predominantly in severely ill

patients)

Nervous system disorders

Common: Headache (severe enough to cause discontinuation in some patients)

Uncommon: Dizziness, somnolence, insomnia, parasthaesias

Eye disorders

Rare: Blurred vision

Vascular disorders

Rare: Peripheral oedema

Respiratory, thoracic and mediastinal disorders

Rare: Bronchospasm

Gastrointestinal disorders

Common: Diarrhoea (severe enough to require discontinuation of therapy in some patients), constipation, abdominal pain

or colic, nausea, vomiting, flatulence

Rare: Dry mouth, stomatitis, oesophageal candidiasis, taste disturbances

Hepato-biliary disorders

Uncommon: Raised liver enzymes

Rare: Hepatitis with or without jaundice, hepatic encephalopathy

Skin and subcutaneous tissue disorders

Uncommon: Skin rash, urticaria, pruritus

Rare: Photosensitivity, bullous eruption, toxic epidermal necrolysis, Stevens-Johnson syndrome, alopecia, erythema

multiforme

Musculoskeletal, connective tissue and bone disorders

Rare: Asthenia, arthralgia, myalgia

Renal and urinary disorders

Rare: Interstitial nephritis

Rare: Interstitial nephritis

Other

Uncommon: Malaise

Rare: Hypersensitivity reactions (e.g. fever, angioedema, bronchospasm, interstitial nephritis) and anaphylactic shock

Special precautions

Effects related to acid inhibition:

During long-term treatment gastric glandular cysts have been reported in increased frequency. These physiological

changes result from pronounced inhibition of gastric acid secretion. Decreased gastric acidity increases gastric counts of

bacteria normally present in the gastro-intestinal tract. Treatment with OMEZ may lead to an increased risk of gastro-

intestinal infections such as Salmonella and Campylobacter.

In the presence of symptoms such as significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis,

or melaena, and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with OMEZ may

alleviate symptoms and delay diagnosis.

KNOWN SYMPTOMS OF OVER-DOSAGE AND PARTICULARS OF ITS TREATMENT

Blurred vision, confusion, diaphoresis, flushing, headache, malaise, nausea and tachycardia have been reported from

over-dosage with omeprazole. There is no specific antidote for overdose with omeprazole.

TREATMENT IS SYMPTOMATIC AND SUPPORTIVE.

Due to extensive protein binding omeprazole is not readily dialysable. Patients in whom overdose is confirmed or

suspected should be referred for medical practitioner/ doctor consultation.

IDENTIFICATION

OMEZ 10: Off-white to pale yellow elliptical to spherical enteric-coated pellets, filled in a hard gelatin capsule with

opaque lavender coloured cap and opaque yellow coloured body. “Omeprazole 10 mg”imprinted with black ink on cap

and “R157”imprinted with black ink on body.

OMEZ 20: Off-white to pale yellow elliptical to spherical enteric-coated pellets, filled in a hard gelatin capsule with

opaque lavender coloured cap and opaque iron grey coloured body. “Omeprazole 20 mg” imprinted with black ink on

cap and “R158”imprinted with black ink on body.

OMEZ 40: Off-white to pale yellow elliptical to spherical enteric-coated pellets, filled in a hard gelatin capsule with

opaque yellow coloured cap and opaque lavender coloured body. “Omeprazole 40 mg”imprinted with black ink on cap

and “R159”imprinted with black ink on body.

PRESENTATION

OMEZ 10: Blister packaging containing 30 capsules

OMEZ 20: Blister packaging containing 30 capsules

White plastic bottles containing 30 capsules

OMEZ 40: Blister packaging containing 14 capsules

STORAGE INSTRUCTIONS

Store below 25°C. Protect from light and moisture.

Store the blisters in the outer carton until required for use.

Store the container well closed.

KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER

OMEZ 10: 34/11.4.3/0299

OMEZ 20: 34/11.4.3/0300

OMEZ 40: 34/11.4.3/0301

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION

Dr. Reddy’s Laboratories (Pty) Ltd

3rd Floor, TA Bank Building

160 Jan Smuts Avenue

Rosebank

2196 Johannesburg

2196 Johannesburg

DATE OF PUBLICATION OF THE PACKAGE INSERT

April 2007

New addition to this site: January 2008

Source: Pharmaceutical Industry

There are no safety alerts related to this product.

20-9-2016

DIDANOSINE Capsule, Delayed Release Pellets [Teva Pharmaceuticals USA, Inc.]

DIDANOSINE Capsule, Delayed Release Pellets [Teva Pharmaceuticals USA, Inc.]

Updated Date: Sep 20, 2016 EST

US - DailyMed

20-9-2016

ZALEPLON Capsule [Unichem Pharmaceuticals (USA), Inc.]

ZALEPLON Capsule [Unichem Pharmaceuticals (USA), Inc.]

Updated Date: Sep 20, 2016 EST

US - DailyMed

20-9-2016

RIFAMPIN Capsule [Lannett Company, Inc.]

RIFAMPIN Capsule [Lannett Company, Inc.]

Updated Date: Sep 20, 2016 EST

US - DailyMed

20-9-2016

ESOMEPRAZOLE STRONTIUM Capsule, Delayed Release [R2 Pharma, LLC]

ESOMEPRAZOLE STRONTIUM Capsule, Delayed Release [R2 Pharma, LLC]

Updated Date: Sep 20, 2016 EST

US - DailyMed

20-9-2016

CEPHALEXIN Capsule [Lake Erie Medical DBA Quality Care Products LLC]

CEPHALEXIN Capsule [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Sep 20, 2016 EST

US - DailyMed

20-9-2016

STOOL SOFTENER (Docusate Sodium) Capsule, Liquid Filled [TARGET Corporation]

STOOL SOFTENER (Docusate Sodium) Capsule, Liquid Filled [TARGET Corporation]

Updated Date: Sep 20, 2016 EST

US - DailyMed

20-9-2016

LOPERAMIDE HYDROCHLORIDE Capsule [Mylan Pharmaceuticals Inc.]

LOPERAMIDE HYDROCHLORIDE Capsule [Mylan Pharmaceuticals Inc.]

Updated Date: Sep 20, 2016 EST

US - DailyMed

20-9-2016

IBUPROFEN Capsule, Coated [GREAT LAKES WHOLESALE, MARKETING, SALES, INC.]

IBUPROFEN Capsule, Coated [GREAT LAKES WHOLESALE, MARKETING, SALES, INC.]

Updated Date: Sep 20, 2016 EST

US - DailyMed

20-4-2016

GABAPENTIN Capsule [Lake Erie Medical DBA Quality Care Products LLC]

GABAPENTIN Capsule [Lake Erie Medical DBA Quality Care Products LLC]

Updated Date: Apr 20, 2016 EST

US - DailyMed

20-4-2016

PROPRANOLOL HYDROCHLORIDE Capsule, Extended Release [Mylan Pharmaceuticals Inc.]

PROPRANOLOL HYDROCHLORIDE Capsule, Extended Release [Mylan Pharmaceuticals Inc.]

Updated Date: Apr 20, 2016 EST

US - DailyMed

20-4-2016

BEXAROTENE Capsule, Liquid Filled [Mylan Institutional Inc.]

BEXAROTENE Capsule, Liquid Filled [Mylan Institutional Inc.]

Updated Date: Apr 20, 2016 EST

US - DailyMed

20-4-2016

NEXIUM (Esomeprazole Magnesium) Capsule, Delayed Release [REMEDYREPACK INC.]

NEXIUM (Esomeprazole Magnesium) Capsule, Delayed Release [REMEDYREPACK INC.]

Updated Date: Apr 20, 2016 EST

US - DailyMed

20-4-2016

NIZATIDINE Capsule [Mylan Pharmaceuticals Inc.]

NIZATIDINE Capsule [Mylan Pharmaceuticals Inc.]

Updated Date: Apr 20, 2016 EST

US - DailyMed

20-1-2016

FENOFIBRIC ACID Capsule, Delayed Release [Actavis Pharma, Inc.]

FENOFIBRIC ACID Capsule, Delayed Release [Actavis Pharma, Inc.]

Updated Date: Jan 20, 2016 EST

US - DailyMed

20-1-2016

BENZONATATE (Benzonatate) Capsule [PD-Rx Pharmaceuticals, Inc.]

BENZONATATE (Benzonatate) Capsule [PD-Rx Pharmaceuticals, Inc.]

Updated Date: Jan 20, 2016 EST

US - DailyMed

20-1-2016

OMEPRAZOLE MAGNESIUM Capsule, Delayed Release [Chain Drug Consortium, LLC]

OMEPRAZOLE MAGNESIUM Capsule, Delayed Release [Chain Drug Consortium, LLC]

Updated Date: Jan 20, 2016 EST

US - DailyMed

20-1-2016

FENOFIBRATE (Fenofibrate) Capsule [AvKARE, Inc.]

FENOFIBRATE (Fenofibrate) Capsule [AvKARE, Inc.]

Updated Date: Jan 20, 2016 EST

US - DailyMed

20-1-2016

GABAPENTIN (Gabapentin) Capsule [AvKARE, Inc.]

GABAPENTIN (Gabapentin) Capsule [AvKARE, Inc.]

Updated Date: Jan 20, 2016 EST

US - DailyMed

20-1-2016

OXYCODONE HYDROCHLORIDE Capsule [Mayne Pharma Inc.]

OXYCODONE HYDROCHLORIDE Capsule [Mayne Pharma Inc.]

Updated Date: Jan 20, 2016 EST

US - DailyMed

20-1-2016

ACYCLOVIR Capsule [Preferred Pharmaceuticals, Inc.]

ACYCLOVIR Capsule [Preferred Pharmaceuticals, Inc.]

Updated Date: Jan 20, 2016 EST

US - DailyMed

20-11-2015

SIGNATURE CARE STOOL SOFTENER (Docusate Sodium) Capsule, Liquid Filled [Safeway]

SIGNATURE CARE STOOL SOFTENER (Docusate Sodium) Capsule, Liquid Filled [Safeway]

Updated Date: Nov 20, 2015 EST

US - DailyMed

20-11-2015

CYCLOPHOSPHAMIDE Capsule [Avera McKennan Hospital]

CYCLOPHOSPHAMIDE Capsule [Avera McKennan Hospital]

Updated Date: Nov 20, 2015 EST

US - DailyMed

20-11-2015

DOXYCYCLATE HYCLATE (Doxycycline Hyclate) Capsule [West-Ward Pharmaceuticals Corp]

DOXYCYCLATE HYCLATE (Doxycycline Hyclate) Capsule [West-Ward Pharmaceuticals Corp]

Updated Date: Nov 20, 2015 EST

US - DailyMed

20-11-2015

ITRACONAZOLE Capsule [Eon Labs, Inc.]

ITRACONAZOLE Capsule [Eon Labs, Inc.]

Updated Date: Nov 20, 2015 EST

US - DailyMed

20-11-2015

LITHIUM CARBONATE Capsule [Glenmark Pharmaceuticals Inc., USA]

LITHIUM CARBONATE Capsule [Glenmark Pharmaceuticals Inc., USA]

Updated Date: Nov 20, 2015 EST

US - DailyMed

20-11-2015

NEXIUM (Esomeprazole Magnesium) Capsule, Delayed Release [Avera McKennan Hospital]

NEXIUM (Esomeprazole Magnesium) Capsule, Delayed Release [Avera McKennan Hospital]

Updated Date: Nov 20, 2015 EST

US - DailyMed

20-10-2015

LITHIUM CARBONATE Capsule [REMEDYREPACK INC. ]

LITHIUM CARBONATE Capsule [REMEDYREPACK INC. ]

Updated Date: Oct 20, 2015 EST

US - DailyMed

20-10-2015

ETHOSUXIMIDE Capsule [Greenstone LLC]

ETHOSUXIMIDE Capsule [Greenstone LLC]

Updated Date: Oct 20, 2015 EST

US - DailyMed

20-10-2015

LOVAZA (Omega-3-Acid Ethyl Esters) Capsule, Liquid Filled [GlaxoSmithKline LLC]

LOVAZA (Omega-3-Acid Ethyl Esters) Capsule, Liquid Filled [GlaxoSmithKline LLC]

Updated Date: Oct 20, 2015 EST

US - DailyMed

20-10-2015

GAS RELIEF (Simethicone) Capsule, Liquid Filled [Kroger Company]

GAS RELIEF (Simethicone) Capsule, Liquid Filled [Kroger Company]

Updated Date: Oct 20, 2015 EST

US - DailyMed

20-10-2015

ESOMEPRAZOLE MAGNESIUM Capsule, Delayed Release [Torrent Pharmaceuticals Limited]

ESOMEPRAZOLE MAGNESIUM Capsule, Delayed Release [Torrent Pharmaceuticals Limited]

Updated Date: Oct 20, 2015 EST

US - DailyMed

Other products with the same active ingredient

Advertisement